

### S.3 Systemic, non-biologic therapies (short term)

Intervention	Population – psoriasis phenotype	N achieving remission (clear/nearly clear or PASI75)		N experiencing:			
		Intervention	Placebo	Withdrawal due to drug toxicity		Serious/named adverse events	
				Intervention	Placebo	Intervention	Placebo
Methotrexate; incremental dosing (+folic acid)	Chronic plaque psoriasis	415/1000	188/1000	55/1000	20/1000	Elevated liver enzymes (>1.5-2.5 ULN) 91/1000	Elevated liver enzymes (>1.5-2.5 ULN) 75/1000
Ciclosporin	Chronic plaque psoriasis	2.5-3 mg 232/1000 5 mg 600/1000	44/1000	0/1000	0/1000	Hypertension 391/1000  Decrease in GFR >15% 3 mg/kg: 333/1000 5 mg/kg: 500/1000	Hypertension 333/1000  Decrease in GFR >15% 0/1000
	Palmoplantar pustulosis	652/1000	200/1000	NA	NA	Hypertension 37/1000	Hypertension 0/1000
Acitretin – 25 mg	Plaque, pustular and erythrodermic psoriasis	480/1000	188/1000	18/1000	0/1000	Cheilitis 850/1000  Hair loss 150/1000  Elevated liver enzymes (>ULN) 200/1000  Elevated cholesterol (>ULN) 0/1000	Cheilitis 300/1000  Hair loss 100/1000  Elevated liver enzymes (>ULN) 0/1000  Elevated cholesterol (>ULN) 53/1000

GFR: Glomerular filtration rate

*NA: Not available*

*ULN: Upper limit of normal*